{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,28]],"date-time":"2025-08-28T00:04:48Z","timestamp":1756339488401,"version":"3.44.0"},"reference-count":8,"publisher":"BMJ","issue":"12","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Case Rep"],"accepted":{"date-parts":[[2022,10,31]]},"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:p>We present a case of a woman in her early 60s with multiple myeloma who, while undergoing treatment with cyclophosphamide, bortezomib and dexamethasone (CyBorD), noticed a whitish nodular swelling on the eyelid. This occurred after one cycle of CyBorD and on subsequent treatment, it also involved the contralateral eyelid. The lesions were initially managed with conservative measures by applying warm compresses, but the lesions progressively increased in size. CyBorD was discontinued and topical antibiotics and anti-inflammatories were initiated, resulting in a decrease in size of the lesions. On resolution of symptoms, she was rechallenged with CyBorD, and symptoms did not recur. The temporal relationship between bortezomib and the development of chalazion is based on connection and no association has been proven.<\/jats:p>","DOI":"10.1136\/bcr-2022-251077","type":"journal-article","created":{"date-parts":[[2022,12,7]],"date-time":"2022-12-07T10:30:54Z","timestamp":1670409054000},"page":"e251077","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":0,"title":["Chalazion in a patient with multiple myeloma treated with bortezomib"],"prefix":"10.1136","volume":"15","author":[{"given":"Bipin","family":"Ghimire","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, Beaumont Hospitals, Royal Oak, Michigan, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuko","family":"Hamajima","sequence":"additional","affiliation":[{"name":"Department on Oncology, University of Texas at Austin Dell Seton Medical Center, Austin, Texas, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lorena","family":"Carbajal-Carballo","sequence":"additional","affiliation":[{"name":"Department of Oncology, University of Texas at Austin Dell Medical School, Austin, Texas, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6941-8312","authenticated-orcid":false,"given":"Nwabundo","family":"Anusim","sequence":"additional","affiliation":[{"name":"Department of Oncology, University of Texas at Austin Dell Medical School, Austin, Texas, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2022,12,7]]},"reference":[{"key":"2025082708001127000_15.12.e251077.1","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1001\/jamaophthalmol.2015.3963","article-title":"Association between bortezomib therapy and eyelid chalazia","volume":"134","author":"Fraunfelder","year":"2016","journal-title":"JAMA Ophthalmol"},{"key":"2025082708001127000_15.12.e251077.2","doi-asserted-by":"crossref","DOI":"10.1186\/s12886-019-1118-x","article-title":"Management and outcomes of proteasome inhibitor associated chalazia and blepharitis: a case series","volume":"19","author":"Sklar","year":"2019","journal-title":"BMC Ophthalmol"},{"key":"2025082708001127000_15.12.e251077.3","doi-asserted-by":"crossref","DOI":"10.4081\/hr.2015.5729","article-title":"Chalazia development in multiple myeloma: a new complication associated with bortezomib therapy","volume":"7","author":"Yun","year":"2015","journal-title":"Hematol Rep"},{"key":"2025082708001127000_15.12.e251077.4","doi-asserted-by":"crossref","first-page":"E80","DOI":"10.1002\/ajh.25382","article-title":"Bortezomib ocular toxicities: outcomes with ketotifen","volume":"94","author":"Dennis","year":"2019","journal-title":"Am J Hematol"},{"key":"2025082708001127000_15.12.e251077.5","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1016\/j.ophtha.2014.04.021","article-title":"Chalazia associated with bortezomib therapy for multiple myeloma","volume":"121","author":"Grob","year":"2014","journal-title":"Ophthalmology"},{"key":"2025082708001127000_15.12.e251077.6","doi-asserted-by":"crossref","first-page":"e381","DOI":"10.1016\/j.jfo.2017.09.029","article-title":"Chalazia associated with bortezomib therapy","volume":"41","author":"Laaribi","year":"2018","journal-title":"J Fr Ophtalmol"},{"key":"2025082708001127000_15.12.e251077.7","article-title":"A case report on bortezomib-induced bilateral chalazion","volume":"12","author":"Paravathaneni","year":"2020","journal-title":"Cureus"},{"key":"2025082708001127000_15.12.e251077.8","first-page":"103283","article-title":"Resolution of bortezomib-associated chalazia\/blepharitis after switch to ixazomib: a case report","volume":"69","author":"Lemoine","year":"2021","journal-title":"Curr Res Transl Med"}],"container-title":["BMJ Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bcr-2022-251077","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,27]],"date-time":"2025-08-27T15:00:18Z","timestamp":1756306818000},"score":1,"resource":{"primary":{"URL":"https:\/\/casereports.bmj.com\/lookup\/doi\/10.1136\/bcr-2022-251077"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12]]},"references-count":8,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2022,12,7]]},"published-print":{"date-parts":[[2022,12]]}},"alternative-id":["10.1136\/bcr-2022-251077"],"URL":"https:\/\/doi.org\/10.1136\/bcr-2022-251077","relation":{},"ISSN":["1757-790X"],"issn-type":[{"type":"electronic","value":"1757-790X"}],"subject":[],"published":{"date-parts":[[2022,12]]}}}